Geron Corporation

NASDAQ:GERN

Biotechnology

Healthcare
$0.99 +4.07%

+$0.05 today

Market cap
$638.38M
Beta
0.60
P/E (TTM)
-12.3
EPS (TTM)
-$0.10
52W Low $1.04High $2.01

Volume 34.97M

Average 16.28M

GERN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Geron CorporationNASDAQ: GERN

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $326K rose 5.8% year over year, ahead of the -2.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 18.5% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.

Context

  • Depreciation & amortization amounted to 0.7% of revenue in FY2025, down 0.9 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +5.8% holds above the trailing-twelve-month pace of -2.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$326K+18.5% QoQ
Last fiscal yearDec 2025
$1.2M-1.4% YoY
LTMMar 2026
$1.22M-2.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.8%——
1 year-1.4%——
3-year CAGR+11.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
1.2M USD
Year-over-year change
-1.4%
4-year CAGR
+11.4%

Depreciation & Amortization vs competitors

How GERN compares with its peers on the latest reported figures

  • GERN's LTM Mar 2026 depreciation & amortization of $1.22M is the 4th largest of the 8 companies compared; the peer median is $873K.
  • Its year-over-year change of -2.6% is the 4th highest of 6, against a peer median of -1.0%.
  • Depreciation & amortization amounts to 0.6% of revenue for GERN, versus a peer median of 1.7%.
GERN Competitors Peer median
Depreciation & Amortization for GERN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$98.28M +8.6%+11.2%1.7%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$12.88M -3.1%+15.8%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$2.41M -1.0%+34.3%0.8%
GERNGeron CorporationLTM Mar 2026$1.22M -2.6%+11.5%0.6%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$873K +7.1%+5.5%2.5%
DMRADamora Therapeutics, Inc.LTM Jun 2024$771K —-58.9%—
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$304K ———
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$152K -97.9%——
Peer median (excluding GERN) $873K-1.0%+11.2%1.7%

Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Depreciation & Amortization783K868K1.03M1.22M1.2M
Deferred Income Tax191K0000
Stock-Based Compensation8.08M8M19.35M31.32M88K
Change in Working Capital10.52M5.03M6.06M(68.41M)(68.54M)
Accounts Receivables(1.04M)(1.38M)1.49M(36.89M)(377K)
Inventory1.04M1.38M0(37.97M)(77.92M)
Accounts Payables(232K)3.5M(4.03M)2.44M2.66M
Other Working Capital10.75M1.52M8.6M4.02M7.1M
Other Non-Cash Items984K626K(10.06M)(8.18M)41.99M
Operating Cash Flow(95.56M)(127.38M)(167.74M)(218.62M)(111.04M)
Capital Expenditures(207K)(431K)(830K)(680K)(49K)
Acquisitions (Net)1.59M(1.23M)179.49M00
Purchases of Investments(177.43M)(258.01M)(475.59M)(476.93M)(304.42M)
Sales of Investments249.59M320.51M296.1M371.61M411.72M
Other Investing Activities(1.59M)1.23M(179.49M)00
Investing Cash Flow71.95M62.07M(180.32M)(106M)107.25M
Debt Repayment24.9M029.7M34.57M0
Common Stock Issued20.39M69.92M213.34M140.73M2.27M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.28M17.35M118.98M159.08M0
Financing Cash Flow48.56M87.26M362.02M334.37M2.27M
Effect of Forex Changes022K(27K)(12K)87K
Net Change in Cash24.95M21.97M13.93M9.74M(1.44M)
Free Cash Flow(95.76M)(127.81M)(168.57M)(219.3M)(111.09M)

Geron Corporation

NASDAQ:GERN

Intrinsic Alpha fair value

Locked

Current Price

$0.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.